• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Better Therapeutics Inc. (Amendment)

    4/13/23 4:43:09 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTTX alert in real time by email
    SC 13G/A 1 mountaincrest_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)*

     

    Better Therapeutics, Inc. (f/k/a Mountain Crest Acquisition Corp. II)
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per Share

     

    (Title of Class of Securities)

     

    08773T104

     

    (CUSIP Number)

     

    April 10, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1 (b)
    ☐Rule 13d-1 (c)
    ☒Rule 13d-1 (d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAME OF REPORTING PERSON

     

    Mountain Crest Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER

     

    1,388,250

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    1,388,250

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,388,250

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.4%(1)

    12

    TYPE OF REPORTING PERSON*

     

    PN

           

    2

     

     

    1

    NAME OF REPORTING PERSON

     

    Dong Liu

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    China

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER

     

    1,388,250

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    1,388,250 

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,388,250

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.4%(1)

    12

    TYPE OF REPORTING PERSON*

     

    IN

           

    (1) The percentage set forth in Row 11 of this Cover Page is calculated based on i) 1,388,250 shares of Common Stock (as defined herein) jointly owned by Mountain Crest Capital LLC and Dong Liu; and ii) 23,852,272 shares of Common Stock outstanding as of March 24, 2023, as reported on the Form 10-K of the Issuer (as defined below) filed with the Securities and Exchange Commission on March 30, 2023, plus 7,878,786 shares of Common Stock issued pursuant to certain private placement closed on or about April 10, 2023, as reported on the Form 8-K of the Issuer filed with the Securities and Exchange Commission on April 7, 2023.

     

    3

     

     

    Item 1.

     

      (a) Name of Issuer:   Better Therapeutics, Inc. (f/k/a Mountain Crest Acquisition Corp. II), a corporation organized under the laws of the State of Delaware (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices: 548 Market Street #49404, San Francisco, CA 94104.

     

    Item 2.

     

      (a) Name of Person Filing:   Mountain Crest Capital LLC and Dong Liu. Dong Liu is the sole manager of Mountain Crest Capital LLC
           
      (b) Address of Principal Business Office or if none, Residence:

     

    The address for this entity/individual is:

    c/o Dong Liu

    311 West 43rd Street, 12th Floor

    New York, NY 10036

     

      (c) Citizenship:  

    Mountain Crest Capital LLC – Delaware

     

    Dong Liu – China

     

    (d)Title of Class of Securities: Common Stock, par value $0.0001 per share

     

    (e)CUSIP Number: 08773T104

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

    (a)Amount Beneficially Owned: 1,388,250

     

    (b)Percent of Class:

     

    Mountain Crest Capital LLC and Dong Liu, its managing member, have voting and dispositive power over the 1,388,250 shares of Common Stock. This accounts for 4.4% of the 31,731,058 shares of Common Stock outstanding as of April 10, 2023, which consists of 23,852,272 shares of Common Stock outstanding as of March 24, 2023, as reported on the Form 10-K of the Issuer filed with the Securities and Exchange Commission on March 30, 2023, plus 7,878,786 shares of Common Stock issued pursuant to certain private placement closed on or about April 10, 2023, as reported on the Form 8-K of the Issuer filed with the Securities and Exchange Commission on April 7, 2023.

     

    4

     

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    Mountain Crest Capital LLC – 1,388,250 shares

     

    Dong Liu - 1,388,250 shares

     

      (ii) shared power to vote or to direct the vote:

     

    Mountain Crest Capital LLC – 0 shares

     

    Dong Liu - 0 shares

     

      (iii) sole power to dispose or to direct the disposition of:

     

    Mountain Crest Capital LLC – 1,388,250 shares

     

    Dong Liu - 1,388,250 shares

     

      (iv) shared power to dispose or to direct the disposition of:

     

    Mountain Crest Capital LLC – 0 shares

     

    Dong Liu - 0 shares

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10. Certifications: Not Applicable

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    April 13, 2023

     

      MOUNTAIN CREST CAPITAL LLC
         
      By: /s/ Dong Liu
        Name: Dong Liu
        Title: Authorized Signatory
         
        /s/ Dong Liu
        Dong Liu

     

    6

    Get the next $BTTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTTX

    DatePrice TargetRatingAnalyst
    11/24/2021$17.00Buy
    Chardan Capital Markets
    11/10/2021Outperform
    Cowen
    More analyst ratings

    $BTTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

      One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

      3/5/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

      Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022. Gomez-Thinnes brings more than two decades of experience in the healthcare industry, leading the commercialization and launch of products spanning the medical device, prescription medicines and consumer health sect

      10/27/22 7:30:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

      Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t

      6/7/22 7:30:00 AM ET
      $BTTX
      $EXEL
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BTTX
    Financials

    Live finance-specific insights

    See more
    • Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape

      3/1/24 9:00:00 AM ET
      $BTCY
      $BTTX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

      Company obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. "We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare providers a clinically proven, convenie

      11/9/23 7:00:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

      Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The

      11/8/23 7:30:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:06 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:09 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Better Therapeutics Inc.

      EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)

      5/29/24 12:15:08 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Better Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00

      11/24/21 7:14:30 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on Better Therapeutics

      Cowen initiated coverage of Better Therapeutics with a rating of Outperform

      11/10/21 6:22:09 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Better Therapeutics Inc. (Amendment)

      SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)

      2/13/24 1:00:29 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Better Therapeutics Inc. (Amendment)

      SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)

      2/12/24 4:28:28 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Better Therapeutics Inc. (Amendment)

      SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)

      1/25/24 4:30:59 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

      Better Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq's continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be d

      3/14/24 9:38:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

      One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

      3/5/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians

      3/4/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perry David P was granted 839,895 shares, increasing direct ownership by 53% to 2,416,634 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      2/13/24 9:50:33 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perry David P was granted 1,471,453 shares, increasing direct ownership by 1,398% to 1,576,739 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      1/10/24 4:19:25 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perry David P was granted 3,750 shares, increasing direct ownership by 4% to 105,286 units (SEC Form 4)

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      12/20/23 5:24:37 PM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care